Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: J Thorac Oncol. 2013 Dec;8(12):1492–1501. doi: 10.1097/JTO.0000000000000007

Figure 3. RALA and RALB expression and activity in human NSCLC cell lines.

Figure 3

(A) RALA and RALB expression in 14 NSCLC cell lines by western blot. Cell lines with KRAS mutation indicated with asterisks. (B) Densitometric quantification of RALA and RALB expression shows their expression is higher in KRAS mutant NSCLC cell lines (P<0.05, student's t-test). (C) RALA and RALB activation levels in the 14 NSCLC cell lines. Cell lines with KRAS mutation indicated with asterisks. (D) Densitometric analysis revealed higher RALA activation in KRAS mutant NSCLC cell lines (P<0.05, student's t-test). No relationship to KRAS was found with RALB. (E) Knockdown of RAL GTPase in H2122 cells following transient transfection with siRNA against RALA (siRALA) and B (siRALB). Cells were lysed 3,6,9,12,15 and 18 days after transfection and RAL GTPase knockdown was determined by western blot. (F) Loss of RALA, B or A+B reduced subcutaneous tumor growth in mice. H2122 cells were transfected with siRNA against RALA (siRALA), B (siRALB) and A+B (siRALA+B), injected in mice and studied for in vivo tumor growth (see Materials and Methods). Luciferase siRNA transfected cells were used as control (siCTL). *P<0.05 by student's t-test.